These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 27868140)

  • 1. Psoriasis as a Manifestation of an Immune Reconstitution in Two Patients with Hepatitis C Treated with Ledipasvir/Sofosbuvir.
    Heppt F; Sticherling M
    Acta Derm Venereol; 2017 Apr; 97(4):526-527. PubMed ID: 27868140
    [No Abstract]   [Full Text] [Related]  

  • 2. Case of Erythema Multiforme Drug Eruption Induced by Ledipasvir/Sofosbuvir.
    Wang Y; Zheng S
    Am J Ther; 2018; 25(5):e586-e587. PubMed ID: 30188425
    [No Abstract]   [Full Text] [Related]  

  • 3. Harvoni (ledipasvir and sofosbuvir) for hepatitis C.
    Mullins C; Gibson W; Klibanov OM
    Nurse Pract; 2015 Nov; 40(11):22-6. PubMed ID: 26474199
    [No Abstract]   [Full Text] [Related]  

  • 4. Sexual Dysfunction in a Patient Taking Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C: A Case Report.
    Lenz DU; Crutcher EL; Greene EM
    J Pharm Pract; 2019 Apr; 32(2):231-235. PubMed ID: 29183252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient leaflet for Harvoni (sofosbuvir + ledipasvir): almost no information on adverse effects.
    Prescrire Int; 2016 Jun; 25(172):162. PubMed ID: 27486652
    [No Abstract]   [Full Text] [Related]  

  • 6. Harvoni (Ledipasvir With Sofosbuvir)-Induced Renal Injury.
    Wanchoo R; Thakkar J; Schwartz D; Jhaveri KD
    Am J Gastroenterol; 2016 Jan; 111(1):148-9. PubMed ID: 26785666
    [No Abstract]   [Full Text] [Related]  

  • 7. Emerging options for treating hepatitis C infection.
    Fantasia HC
    Nurs Womens Health; 2015; 19(2):183-7. PubMed ID: 25900589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
    [No Abstract]   [Full Text] [Related]  

  • 9. Classical Kaposi's sarcoma concurrent with ledipasvir-sofosbuvir therapy for hepatitis C infection.
    Latini A; Orsini D; Ambrifi M; Colafigli M; Zaccarelli M; Cristaudo A
    G Ital Dermatol Venereol; 2019 Oct; 154(5):593-594. PubMed ID: 29192474
    [No Abstract]   [Full Text] [Related]  

  • 10. Eight Weeks Treatment With Sofosbuvir/Ledipasvir in a 4-year-old Child With Chronic Hepatitis C Virus Genotype 1 Infection.
    Graf Einsiedel H; Christiansen H; Wiegand J
    Pediatr Infect Dis J; 2016 Dec; 35(12):1373. PubMed ID: 27832030
    [No Abstract]   [Full Text] [Related]  

  • 11. Association of Ledipasvir-Sofosbuvir Treatment With Uveitis in Patients Treated for Hepatitis C.
    Padidam S; Burke MT; Apple DB; Hu JK; Lin X
    JAMA Ophthalmol; 2019 May; 137(5):568-570. PubMed ID: 30920588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children.
    Rizza SA; Nehra V; Temesgen Z
    Drugs Today (Barc); 2017 Aug; 53(8):447-451. PubMed ID: 29119149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Ledipasvir / sofosbuvir-benefit assessment according to § 35a SGB V the G-BA].
    Berg T; Zeuzem S; Manns MP
    Z Gastroenterol; 2015 May; 53(5):519-23. PubMed ID: 26167554
    [No Abstract]   [Full Text] [Related]  

  • 14. Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
    Prescrire Int; 2015 Dec; 24(166):285-9. PubMed ID: 26788571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New-onset cutaneous lichen planus following therapy for hepatitis C with ledipasvir-sofosbuvir.
    Scott GD; Rieger KE
    J Cutan Pathol; 2016 Apr; 43(4):408-9. PubMed ID: 26816004
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C.
    Fazel Y; Lam B; Golabi P; Younossi Z
    Expert Opin Drug Saf; 2015 Aug; 14(8):1317-26. PubMed ID: 26043900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
    Kowdley KV; Gordon SC; Reddy KR; Rossaro L; Bernstein DE; Lawitz E; Shiffman ML; Schiff E; Ghalib R; Ryan M; Rustgi V; Chojkier M; Herring R; Di Bisceglie AM; Pockros PJ; Subramanian GM; An D; Svarovskaia E; Hyland RH; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Pound D; Fried MW;
    N Engl J Med; 2014 May; 370(20):1879-88. PubMed ID: 24720702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
    Afdhal N; Zeuzem S; Kwo P; Chojkier M; Gitlin N; Puoti M; Romero-Gomez M; Zarski JP; Agarwal K; Buggisch P; Foster GR; Bräu N; Buti M; Jacobson IM; Subramanian GM; Ding X; Mo H; Yang JC; Pang PS; Symonds WT; McHutchison JG; Muir AJ; Mangia A; Marcellin P;
    N Engl J Med; 2014 May; 370(20):1889-98. PubMed ID: 24725239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute liver failure during hepatitis C treatment with sofosbuvir and ledipasvir.
    Debes JD; Ricci P
    Dig Liver Dis; 2015 Dec; 47(12):1091-2. PubMed ID: 26427585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.